Efficacy Analysis of Levosimendan in the Treatment of Heart Failure Caused by Severe Coronary Heart Disease

Song MEI; Wen JIANG; Xiang-feng BAI; Wen-jie WANG; Dan HUANG; Wei CAO

doi:10.12259/j.issn.2095-610X.S20210121

Volume 42 Issue 1

Jan. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2021 > 42(1): 72-75

Song MEI, Wen JIANG, Xiang-feng BAI, Wen-jie WANG, Dan HUANG, Wei CAO. Efficacy Analysis of Levosimendan in the Treatment of Heart Failure Caused by Severe Coronary Heart Disease[J]. Journal of Kunming Medical University, 2021, 42(1): 72-75. doi: 10.12259/j.issn.2095-610X.S20210121

Citation:

Song MEI, Wen JIANG, Xiang-feng BAI, Wen-jie WANG, Dan HUANG, Wei CAO. Efficacy Analysis of Levosimendan in the Treatment of Heart Failure Caused by Severe Coronary Heart Disease[J]. Journal of Kunming Medical University, 2021, 42(1): 72-75. doi: 10.12259/j.issn.2095-610X.S20210121

Citation:

Song MEI, Wen JIANG, Xiang-feng BAI, Wen-jie WANG, Dan HUANG, Wei CAO. Efficacy Analysis of Levosimendan in the Treatment of Heart Failure Caused by Severe Coronary Heart Disease[J]. Journal of Kunming Medical University, 2021, 42(1): 72-75. doi: 10.12259/j.issn.2095-610X.S20210121

PDF( 599 KB)

Efficacy Analysis of Levosimendan in the Treatment of Heart Failure Caused by Severe Coronary Heart Disease

doi: 10.12259/j.issn.2095-610X.S20210121

Dept. of Cardiovascular Surgery，The 1st Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650032，China

Received Date: 2020-08-22
Available Online: 2021-01-26
Publish Date: 2021-01-26

Abstract

Abstract

Objective To analyze the efficacy and safety of levosimendan in patients with heart failure caused by severe coronary heart disease. Methods From January 2018 to January 2020, 40 patients who were hospitalized with the diffuse coronary artery disease were selected and divided into two groups according to the selection of levosimendan or not, with 20 cases in each group. Cardiac function index, myocardial enzymes, BNP, liver and kidney function changes and adverse reactions of the two groups were collected and analyzed. Results After the corresponding treatment, it was found that changes in cardiac function were statistically significant（P < 0.05）and differences in myocardial enzymes and BNP were statistically significant（P < 0.05）between the two groups. Also, there was no significant difference in liver and kidney function（P > 0.05）and the incidence of adverse reactions was not statistically significant（P > 0.05）. Conclusion The effect of levosimendan on severe coronary heart disease is obvious and the side effects of the drug are small.
- Severe coronary heart disease,
- Levosimendan,
- Heart failure

FullText(HTML)

References(15)

References

[1]	Farooq V,van Klaveren D,Steyerberg E W,et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients:development and validation of SYNTAX score II[J]. The Lancet,2013,381(9867):639-650. doi: 10.1016/S0140-6736(13)60108-7
[2]	Revermann M,Schloss M,Mieth A,et al. Levosimendan attenuates pulmonary vascular remodeling[J]. Intensive Caremed,2011,37(8):1368-1377. doi: 10.1007/s00134-011-2254-9
[3]	Domaradzki W,Sanetra K,Krauze J,et al. Coronary endarterectomy in leftanterior descending artery combined with coronary artery bypass graftingmidterm mortality and morbidity[J]. Kardiochir Torakochirurgia Pol,2015,12(4):304-308.
[4]	Lv M Y,Deng S L,Long X F. rhBNP therapy can improve clinical outcomes and reduce in-hospital mortality compared with dobutamine in heart failure patients:a meta-analysis[J]. Br J Clin Pharmacol,2016,81(1):174-185. doi: 10.1111/bcp.12788
[5]	杜贺,史承勇. 左西孟旦的研究新进展[J].中国循环杂志,2014,29(7):555-557. doi: 10.3969/j.issn.1000-3614.2014.07.020
[6]	徐芳,李铁成. 左西孟旦对老年冠状动脉旁路移植术患者生存及预后的影响[J].中国动脉硬化杂志,2019,27(12):1075-1079. doi: 10.3969/j.issn.1007-3949.2019.12.013
[7]	陈志刚. 左西孟旦对重症难治性心力衰竭患者血清脑利钠肽及尿酸水平的影响[J].临床合理用药杂志,2020,13(11):27-28.
[8]	Elin M Thorlacius,Håkan Wåhlander,Tiina Ojala,et al. Levosimendan versus milrinone for inotropic support in pediatric cardiac surgery:Results from a randomized trial[J]. Journal of Cardiothoracic and Vascular Anesthesia,2020,34(8):10-13.
[9]	张洪钦. 左西孟旦与多巴酚丁胺治疗急性失代偿性心力衰竭疗效和血液学指标比较[J].临床合理用药杂志,2020,13(8):3-4.
[10]	杨文清,陈涛. 左西孟旦治疗老年重度心力衰竭的疗效及安全性分析[J].中国农村卫生,2020,12(4):87-89. doi: 10.3969/j.issn.1674-361X.2020.04.087
[11]	陶硕秋,祁宏. 左西孟旦治疗射血分数减低慢性心衰患者的疗效及对心功能、炎症指标等的影响[J].心血管康复医学杂志,2020,29(1):68-72. doi: 10.3969/j.issn.1008-0074.2020.01.17
[12]	菲尔凯提·玉山江,穆叶赛·尼加提. 急性冠状动脉综合征合并急性心力衰竭的药物治疗进展[J].慢性病学杂志,2020,21(1):49-51.
[13]	张美兰. 左西孟旦治疗老年重度心力衰竭的疗效及安全性分析[J].中西医结合心血管病电子杂志,2019,7(35):55-58.
[14]	冯婧,鲁佳佳,赵琳. 重组人脑利钠肽联合左西孟旦对老年急性失代偿性心力衰竭患者心功能和血清N末端B型脑钠肽前体及和肽素水平的影响[J].中国医药,2020,15(5):665-668.
[15]	陈志平. 左西孟旦联合缬沙坦治疗老年重症心力衰竭的疗效及不良反应率观察[J].心血管病防治知识(学术版),2019,9(22):29-31.

Relative Articles(20)

Relative Articles

[1]	Yan QIU, Yinli WANG, Mengmeng YANG, Liangmin GUO, Longhui YUAN. Association between MPV，PDW，PCT and Cardiac Function in Patients with Pulmonary Hypertension. Journal of Kunming Medical University, 2023, 44(12): 121-126. doi: 10.12259/j.issn.2095-610X.S20231219
[2]	Mei YANG, Ping WANG, Hui YANG, Gonghao HE. Potential Therapeutic Targets and Research Progress of Related Drugs of Heart Failure. Journal of Kunming Medical University, 2023, 44(7): 156-161. doi: 10.12259/j.issn.2095-610X.S20230719
[3]	Wei-jie SU, Mei-sha ZHANG, Jia-ning LI, Ying LIU, Ding-jie XU, Hong CHANG. Establishment of Rat Myoblast Atrophy Model Induced by Ang Ⅱ. Journal of Kunming Medical University, 2021, 42(10): 8-13. doi: 10.12259/j.issn.2095-610X.S20211026
[4]	Li Jie , Zhang Shi Ming , Yang Shu Lian . . Journal of Kunming Medical University, 2020, 41(01): 31-36.
[5]	Zhang Ti Ling , Zhang Wei Hua , Luo Qing 祎, Xia Hong Ying , Lu Yi Bing . . Journal of Kunming Medical University, 2020, 41(03): 91-95.
[6]	Jian-pei SU, Wei-meng TIAN, Jun GU, Mi-yu HE. Association between C-reactive Protein/Albumin Ratio and Long-term Prognosis in Elderly Patients with Heart Failure. Journal of Kunming Medical University, 2020, 41(12): 128-132. doi: 10.12259/j.issn.2095-610X.S20201236
[7]	Zhao Xin Mei , Li Jun Mei , Yang Ju Hua , Zhao Cun Na , Zhang Pei , Huang Xiao , Wang Xiao Yan , Li Hai , Zhang Yuan Fei . . Journal of Kunming Medical University, 2019, 40(05): 144-148.
[8]	Zou Hong Lin , Jia Zheng , Xing Zheng Jiang , Li Ya Xiong , Wei Jie , Sun Xiao Lin , Meng Fan Di , Liu Fei Fei . . Journal of Kunming Medical University, 2019, 40(09): 62-67.
[9]	Wang Xu , Deng Hong , Li Ming Zhou , Xing Xi Qian . . Journal of Kunming Medical University, 2018, 39(09): 87-90.
[10]	Shi Ye , Niu Xiao Qun , Cao Yu , Li Hui . . Journal of Kunming Medical University, 2017, 38(02): 78-81.
[11]	Ye Xue Qun , Nie Lei . . Journal of Kunming Medical University, 2017, 38(02): 95-98.
[12]	Luo Yong Li . Clinical Assessment on the Safety of Cardiac Rehabilitation for the Elderly Patients with Chronic Heart Failure. Journal of Kunming Medical University,
[13]	Li Yan Ping . The Clinical Characteristics of Patients with Chronic Heart Failure with Preserved Ejection Fraction. Journal of Kunming Medical University,
[14]	Yuan Hua Yuan . . Journal of Kunming Medical University,
[15]	Zhang Ji Lei . . Journal of Kunming Medical University,
[16]	Chen Qiu . . Journal of Kunming Medical University,
[17]	Dai Hai Long . . Journal of Kunming Medical University,
[18]	Ding Cheng Yan . . Journal of Kunming Medical University,
[19]	Chang Song Jie . . Journal of Kunming Medical University,
[20]	. Clinical Analysis of 59 Old Chronic Heart Failure Patients Complicated with Hyponatremia. Journal of Kunming Medical University,